Multiple Sclerosis

The FDA has issued a warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) who received treatment with alemtuzumab (Lemtrada).

With $5 million appropriated from Congress, CDC is launching a National Neurological Conditions and Surveillance System to help increase understanding of neurological disorders and to further support neurologic research, starting with multiple sclerosis and Parkinson disease.

Lifestyle factors like exercise, meditation, and alcohol use were inversely associated with depression risk, while smoking significantly predicted depression.

Multiple sclerosis (MS) is a progressive neurological disease that requires timely management, and a panel of neurologists has developed an internationally applicable standard of care for timely management in patients with MS.

The FDA has issued a safety warning that patients who stopped taking Gilenya experienced worsening of multiple sclerosis, compared with before treatment started or during treatment, in rare cases.

A retrospective study by Houtchens et al on annual pregnancy rates from 2006 to 2014 reveals that US women with multiple sclerosis (MS) had increased pregnancy rates as compared to women without MS.

Here are the top 5 articles for the month of September.

In a review of sex hormones and their role in the development of multiple sclerosis (MS), Ysrraelit and Correale compiled multiple references to provide clinical details regarding hormones and their respective immunological mechanisms.

For patients with multiple sclerosis (MS) being treated with natalizumab, cognitive function improved from baseline to 1 year and improved significantly across all domains from baseline to 2 years.

Noting a disconnect between evidence of benefit and uptake of exercise in patients with multiple sclerosis (MS), researchers offer behavioral science, specifically Social Cognitive Theory, as an approach to increasing participation.

The Multiple Sclerosis-Secondary Progressive Multi-Arm Randomization Trial (MS-SMART) is the first multiarm trial designed specifically to address the unmet need for further identification of neuroprotective drugs in secondary progressive multiple sclerosis.

A recent study has discovered that B cells mediate spontaneous T cell proliferation through the HLA-DR15 haplotype, and this interaction between T cells and B cells may serve as a key factor in understanding the pathogenesis of multiple sclerosis (MS).

As levels of disability increased among patients with multiple sclerosis (MS), cost of illness increased and health-related quality of life decreased.

Findings from a retrospective study comparing typical and myelocortical multiple sclerosis (MS) identified major pathological differences between the 2 MS subtypes and determined that demyelination and neuronal degeneration are independent processes.

New study findings have identified a subtype of multiple sclerosis—myelocortical multiple sclerosis—that has neuronal loss but no demyelination of the brain’s white matter, indicating that demyelination and neuronal degeneration occur independently.

Researchers evaluating the different methods used to predict the progression of multiple sclerosis (MS) found that human–machine hybrid predictions led to better prognoses than did machine learning algorithms or groups of humans alone.

A study has shed new light into the role of extracellular vesicles (EVs) in multiple sclerosis (MS) and how fingolimod, an immunomodulator drug, affects EVs.

More than half of patients with multiple sclerosis (MS) in the BETASLEEP study indicated poor sleep quality, which was linked to fatigue and reduced quality of life over time.

Researchers recently developed a systematic map of the cell types that make up the mouse nervous system which has the ability to reveal new information about the origin of neurological diseases, and may lead to a detailed map of the human brain.

Results from a long-term observational study found that disease-modifying therapies lowered conversion rates to secondary progressive multiple sclerosis (MS) among patients with relapsing-remitting multiple sclerosis.

A recent study found that the association between vitamin D (Vit D) status and multiple sclerosis (MS) susceptibility is genotype dependent and suggested that the outcome of Vit D status in MS is determined by gene-by-sex interactions.

A study recently published in Brain and Behavior has shown that certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis (MS) within the first year following diagnosis of clinically isolated syndrome (CIS).

A recent study aimed to evaluate the burden of age of onset of cardiovascular conditions in a US population with multiple sclerosis, neuromyelitis optica spectrum disorder, or transverse myelitis and found that cardiovascular conditions are as common in those with demyelinating diseases compared with unaffected individuals.

A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.

A recent study analyzed the role of purinergic receptor P2X4 in microglia/macrophages during autoimmune inflammation, finding that P2X4 receptors modulate microglia/macrophage inflammatory responses and identify allosteric modulator ivermectin (IVM) as a potential candidate to promote the repair of myelin damage.